

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 November 2023 (30.11.2023)



(10) International Publication Number
WO 2023/230276 A1

(51) International Patent Classification:
C12N 5/0783 (2010.01) A61P 35/00 (2006.01)
A61K 39/00 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:
PCT/US2023/023601

(22) International Filing Date:
25 May 2023 (25.05.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/346,709 27 May 2022 (27.05.2022) US
63/485,623 17 February 2023 (17.02.2023) US
63/490,162 14 March 2023 (14.03.2023) US

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(71) Applicant: **KITE PHARMA, INC.** [US/US]; c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California
94404 (US).

(72) Inventors: **HASO, Waleed**; Kite Pharma, Inc., c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California
94404 (US). **CAI, Qi**; Kite Pharma, Inc., c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California
94404 (US). **NGUYEN YIP, Thanh**; Kite Pharma, Inc., c/o
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,
California 94404 (US). **TSAL, Hsing-Chuan**; Kite Pharma,
Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster
City, California 94404 (US). **WARREN, Carmen**; Kite
Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, California 94404 (US). **GERAGOSIAN,
Melody**; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US).

(74) Agent: **LOPEZ, Miguel A.** et al.; Kite Pharma, Inc., c/o
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California
94404 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: COMPOSITIONS AND METHODS FOR PREPARING ENGINEERED LYMPHOCYTES FOR CELL THERAPY

(57) Abstract: Provided herein are compositions and methods for manufacturing engineered lymphocytes. Also provided are the prepared engineered lymphocytes which have increased proportions of juvenile/naive lymphocytes leading to increased therapeutic efficacy. The methods in various embodiments are expedited as compared to the conventional technology, and produce lymphocytes with improved viability, transduction success rates, and *in vivo* antitumor efficacy.

WO 2023/230276 A1